251 related articles for article (PubMed ID: 17606312)
1. Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.
Lelievre V; Favrais G; Abad C; Adle-Biassette H; Lu Y; Germano PM; Cheung-Lau G; Pisegna JR; Gressens P; Lawson G; Waschek JA
Peptides; 2007 Sep; 28(9):1688-99. PubMed ID: 17606312
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical investigation of vasoactive intestinal polypeptide in the colon of patients with Hirschsprung's disease.
Tsuto T; Okamura H; Fukui K; Obata HL; Terubayashi H; Iwai N; Majima S; Yanaihara N; Ibata Y
Neurosci Lett; 1982 Dec; 34(1):57-62. PubMed ID: 6761608
[TBL] [Abstract][Full Text] [Related]
3. Interaction of NO and VIP in gastrointestinal smooth muscle relaxation.
Van Geldre LA; Lefebvre RA
Curr Pharm Des; 2004; 10(20):2483-97. PubMed ID: 15320758
[TBL] [Abstract][Full Text] [Related]
4. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
5. [Vasoactive intestinal polypeptide (VIP)--possible importance in diseases of childhood].
Heinz-Erian P; Said SI
Padiatr Padol; 1985; 20(3):221-30. PubMed ID: 2993982
[TBL] [Abstract][Full Text] [Related]
6. Is the reduction of VIP the clue to the pathophysiology of Hirschsprung's disease?
Larsson LT; Sundler F
Z Kinderchir; 1990 Jun; 45(3):164-6. PubMed ID: 2375187
[TBL] [Abstract][Full Text] [Related]
7. CART-peptide immunoreactivity in enteric nerves in patients with Hirschsprung's disease.
Gunnarsdóttir A; Wierup N; Larsson LT; Kuhar MJ; Ekblad E
Eur J Pediatr Surg; 2007 Jun; 17(3):184-9. PubMed ID: 17638157
[TBL] [Abstract][Full Text] [Related]
8. Disturbances of colonic motility in mouse models of Hirschsprung's disease.
Roberts RR; Bornstein JC; Bergner AJ; Young HM
Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G996-G1008. PubMed ID: 18276829
[TBL] [Abstract][Full Text] [Related]
9. Fine structure of neurons synthesizing vasoactive intestinal peptide in the human colon from patients with Hirschsprung's disease.
Tsuto T; Obata-Tsuto HL; Iwai N; Takahashi T; Ibata Y
Histochemistry; 1989; 93(1):1-8. PubMed ID: 2613543
[TBL] [Abstract][Full Text] [Related]
10. Peptidergic nerves in Hirschsprung's disease and its allied disorders.
Tomita R; Munakata K; Kurosu Y
Eur J Pediatr Surg; 1994 Dec; 4(6):346-51. PubMed ID: 7538322
[TBL] [Abstract][Full Text] [Related]
11. Functional response to vasoactive intestinal peptide in piebald lethal mice.
Caniano DA; Grace GT; Sun CC; Ormsbee HS; Hardy FE; Hill JL
J Pediatr Surg; 1986 Dec; 21(12):1128-32. PubMed ID: 3794977
[TBL] [Abstract][Full Text] [Related]
12. Dysfunction of neurogenic VIP-mediated relaxation in mouse distal colon with dextran sulfate sodium-induced colitis.
Kato E; Yamane S; Nomura R; Matsumoto K; Tashima K; Horie S; Saito T; Fujino H; Murayama T
Pharmacol Res; 2012 Feb; 65(2):204-12. PubMed ID: 21939768
[TBL] [Abstract][Full Text] [Related]
13. Upper gut motility of Hirschsprung's disease and its allied disorders in adults.
Tomita R; Ikeda T; Fujisaki S; Shibata M; Tanjih K
Hepatogastroenterology; 2003; 50(54):1959-62. PubMed ID: 14696442
[TBL] [Abstract][Full Text] [Related]
14. Colonic vasoactive intestinal polypeptide in ulcerative colitis.
Surrenti C; Renzi D; Garcea MR; Surrenti E; Salvadori G
J Physiol Paris; 1993; 87(5):307-11. PubMed ID: 8298608
[TBL] [Abstract][Full Text] [Related]
15. Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.
Banks MR; Farthing MJ; Robberecht P; Burleigh DE
Br J Pharmacol; 2005 Apr; 144(7):994-1001. PubMed ID: 15711593
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of experimental colitis on fluid absorption in rat jejunum: role of the enteric nervous system, VIP, and nitric oxide.
Mourad FH; Barada KA; Bou Rached NA; Khoury CI; Saadé NE; Nassar CF
Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G262-8. PubMed ID: 16123200
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury.
Luo Q; Wang Y; Feng D; Xu Y; Xu L
Eur J Pharmacol; 2009 Apr; 607(1-3):226-33. PubMed ID: 19222997
[TBL] [Abstract][Full Text] [Related]
19. Distribution of the VPAC2 receptor in peripheral tissues of the mouse.
Harmar AJ; Sheward WJ; Morrison CF; Waser B; Gugger M; Reubi JC
Endocrinology; 2004 Mar; 145(3):1203-10. PubMed ID: 14617572
[TBL] [Abstract][Full Text] [Related]
20. Neuroimmune interaction in the gut: from bench to bedside.
Boeckxstaens GE
Verh K Acad Geneeskd Belg; 2006; 68(5-6):329-55. PubMed ID: 17313093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
